bsm-33112M

[Primary Antibody]

Bioss ANTIBODIES

www.bioss.com.cn sales@bioss.com.cn techsupport@bioss.com.cn 400-901-9800

Flow-Cyt (1ug/Test)

CD41/ITGA2B Mouse mAb

- DATASHEET -

Host: Mouse Isotype: IgG1
Clonality: Monoclonal CloneNo.: 9B10
GeneID: 3674 SWISS: P08514

Target: CD41/ITGA2B

Purification: affinity purified by Protein G

Concentration: 1mg/ml

Storage: Size: 50ul/100ul/200ul

0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50%

Glycerol.

Size: 200ug (PBS only)

0.01M PBS

Shipped at 4°C. Store at -20°C for one year. Avoid repeated

freeze/thaw cycles.

Background: This gene encodes a member of the integrin alpha chain family of

proteins. The encoded preproprotein is proteolytically processed to generate light and heavy chains that associate through disulfide linkages to form a subunit of the alpha-IIb/beta-3 integrin cell adhesion receptor. This receptor plays a crucial role in the blood coagulation system, by mediating platelet aggregation. Mutations in this gene are associated with platelet-type bleeding disorders, which are characterized by a failure of platelet aggregation, including Glanzmann thrombasthenia. [provided by RefSeq, Jan

2016]


Reactivity: Human

Predicted MW.: 125 kDa


Applications: WB (1:500-2000)

Subcellular Location: Cell membrane

VALIDATION IMAGES



Sample: Lane 1: HL60 (Human) Cell Lysate at 30 ug Lane 2: Raji (Human) Cell Lysate at 30 ug Primary: Anti-CD41/Integrin alpha 2b (bsm-33112M) at 1/1000 dilution Anti-beta-Actin (bs-0061R) at 1/2000 dilution Secondary: IRDye800CW Goat Anti-Mouse IgG at 1/20000 dilution Predicted band size: 125 kD Observed band size: 125 kD



scatter diagram showing peripheral blood lymphocytes stained with bsm-33112M. The cells were incubated with the antibody (bsm-33112M, 1ug/Test) for 30 min at 22°C. Acquisition of >10,000 events was performed.

— SELECTED CITATIONS —

• [IF=20.3] Lingling Zhang. et al. Bioengineered platelet nanoplatform enables renal-targeted dexamethasone delivery for chronic nephritis therapy with dual anti-inflammatory/anti-fibrotic effects and minimized systemic toxicity. BIOACT MATER. 2025 Oct;52:213 WB; Rat. 40535704